Clinical significance of endothelin-1 and angiotensin-2 levels in patients with post-COVID syndrome according to the timing of rehabilitation therapy
https://doi.org/10.36604/1998-5029-2026-99-42-54
Abstract
Introduction. Post-COVID syndrome (PCS) leads to multiorgan dysfunction, the primary pathophysiological basis of which is considered to be endothelial dysfunction – a state of imbalance among vasoactive and angiogenic mediators.
Aim. To evaluate the clinical relevance of endothelin-1 (EDN1) and angiotensin-2 (ANG-2) levels in PCS patients in relation to the timing of enrollment in rehabilitation treatment.
Materials and methods. The study included 190 patients diagnosed with PCS and 30 healthy controls with no prior history of COVID-19. Assessments encompassed clinical, functional, and laboratory evaluations, including enzyme-linked immunosorbent assay (ELISA) for serum levels of ANG-2, EDN1, bactericidal/permeability-increasing protein (BPI), and C-reactive protein (CRP). Pulmonary function was assessed by spirometry. Physical performance was measured using the 6-minute step test (6MST), dyspnea severity via the Baseline Dyspnea Index (BDI). Fatigue was assessed using the Fatigue Assessment Scale (FAS), and health-related quality of life by the SF-36 questionnaire.
Results. Patients were stratified into four groups based on PCS duration: Group I (<6 months), Group II (6–12 months), Group III (12–24 months), and Group IV (>24 months). Cardiovascular comorbidities predominated in Groups I and II, whereas bronchial asthma and chronic bronchitis were more common in Groups III and IV. Notably, 11.5 % of patients developed respiratory diseases de novo after COVID-19. ANG-2 levels were elevated across all PCS groups compared to controls. EDN1 concentrations were highest in Group I (52.3 [33.3; 62.5] pg/mL) versus controls (44.4 [39.81; 47.22] pg/mL) and showed a progressive decline with longer PCS duration: Group II – 39.4 [26.4; 50.0] pg/mL; Group III – 23.2 [16.0; 40.7] pg/mL; Group IV – 18.7 [16.5; 21.7] pg/mL. FAS and SF-36 scores revealed persistent chronic fatigue and reduced quality of life – both physical and mental – among PCS patients.
Conclusion. For up to two years following acute COVID-19, patients exhibit signs of unresolved low-grade inflammation and impaired endothelial vasomotor function, which underlie persistent PCS symptoms, including chronic fatigue and diminished quality of life.
Keywords
About the Authors
L. Sh. DudchenkoRussian Federation
Leila Sh. Dudchenko, MD, PhD (Med.), Head of the Department
Research Department of Pulmonology
298603; 10/3 Muchin Str.; Yalta
V. A. Beloglazov
Russian Federation
Vladimir A. Beloglazov, MD, PhD, DSc (Med.), Professor, Head of the Department
Department of Internal Medicine № 2
295000; 5/7 Lenin Boulevard; Simferopol
I. A. Yatskov
Russian Federation
Igor A. Yatskov, MD, PhD (Med.), Associate Professor
Department of Internal Medicine № 2
295000; 5/7 Lenin Boulevard; Simferopol
G. N. Andreeva
Russian Federation
Galina N. Andreeva, Staff Scientist
Research Department of Pulmonology
298603; 10/3 Muchin Str.; Yalta
E. A. Solovyova
Russian Federation
Elena A. Solovyova, Staff Scientist
Research Department of Pulmonology
298603; 10/3 Muchin Str.; Yalta
I. V. Shulyak
Russian Federation
Irina V. Shulyak, Head of the Laboratory
Clinical Diagnostic Laboratory
298603; 10/3 Muchin Str.; Yalta
References
1. Ivannikov A.A., Esaulenko A.N., Vasil'chenko M.K., Alidzhanova Kh.G., Petrikov S.S. [COVID-19 and the cardiovascular system. Part II. Post-COVID-19 syndrome]. Neotlozhnaya meditsinskaya pomoshch′. Zhurnal im. N.V. Sklifosovskogo = Russian Sklifosovsky Journal of Emergency Medical Care 2021; 10(2):248–258 (in Russian). doi: 10.23934/2223-9022-2021-10-2-248-258
2. Blann A.D., Heitmar R. SARS-CoV-2 and COVID-19: a narrative review. Br. J. Biomed. Sci. 2022; 79:10426. doi: 10.3389/bjbs.2022.10426
3. Goërtz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Machado F.V.C., Houben-Wilke S., Burtin C., Posthuma R., Franssen F.M.E., van Loon N., Hajian B., Spies Y., Vijlbrief H., van 't Hul A.J., Janssen D.J.A., Spruit M.A. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020; 6(4):00542-2020. doi: 10.1183/23120541.00542-2020
4. Vaduganathan M., Vardeny O., Michel T., McMurray J.J.V., Pfeffer M.A., Solomon S.D. Renin-angiotensin-aldos-terone system inhibitors in patients with COVID-19. N. Engl. J. Med. 2020; 382(17):1653–1659. doi: 10.1056/NEJMsr2005760
5. Vikulova O.K., Zuraeva Z.T., Nikankina L.V., Shestakova M.V. [Role of the renin-angiotensin system and angiotensin-converting enzyme type 2 in the development and course of COVID-19 virus infection in patients with diabetes mellitus]. Sakharniy diabet = Diabetes Mellitus 2020; 23(3):242–249 (in Russian). doi: 10.14341/DM12527
6. Khaytovich A.B. [Coronaviruses (taxonomy, virus structure)]. Krymskiy zhurnal eksperimental'noy i klinicheskoy meditsiny = Crimea Journal of Experimental and Clinical Medicine 2020; 10(3):69–75 (in Russian). doi: 10.37279/2224-6444-2020-10-3-69-81
7. Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020; 581(7807):215–220. doi: 10.1038/s41586-020-2180-5
8. Mason R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur. Respir. J. 2020; 55(4):2000607. doi: 10.1183/13993003.00607-2020
9. Libby P., Lüscher T. COVID-19 is, in the end, an endothelial disease. Eur. Heart J. 2020; 41(32):3038–3044. doi: 10.1093/eurheartj/ehaa623
10. Zhang H., Penninger J., Li Y., Zhong N., Slutsky A. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46(4):586–590. doi: 10.1007/s00134-020-05985-9
11. Shchukina E.V., Shesterina Yu.B., Maylyan D.E., Cherkashchenko S.O., Pivnev B.A., Martynenko A.Yu., Mel'nikov A.Yu. [The role of systemic inflammation in the implementation of the risk of severe coronavirus infection and the probability of developing post-COVID syndrome]. Aktual'nye problemy meditsiny = Actual Problems of Medicine 2023; 46(2):113–122 (in Russian). doi: 10.52575/2712-7456-2023-46-2-113-122
12. Mansell V., D'Cruz R., Fry S. Long COVID and older people. Lancet Healthy Longev. 2022; 3(12):e849–e854. doi: 10.1016/S2666-7568(22)00265-2
13. Peretechikova A.V., Voskresenskaya O.N. [Factors influencing the quality of life of patients with neurological manifestations of post-COVID syndrome]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2024; 124(9):44–50 (in Russian). doi: 10.17116/jnevro202412409144
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166(1):111–117. doi: 10.1164/ajrccm.166.1.at1102
15. Kukol L.V., Pupyshev S.A., Pupyshev A.V., Erdneev B.A. [Dyspnea assessment in elderly patients with chronic obstructive pulmonary disease]. Vestnik Sankt-Peterburgskogo universiteta. Medicina = Vestnik of Saint Petersburg University. Medicine 2012; 3(34–42) (in Russian). EDN: PDRHDJ.
16. [Temporary guidelines of the Russian Ministry of Health. Medical rehabilitation for patients with novel coronavirus infection (COVID-19). Version 3 (01.11.2022)]. Moscow; 2022 (in Russian). Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/060/777/original/VMR_medreabilit_COVID-19_v3.pdf (accessed 11. 02. 2025).
17. Ware J.E., Kosinski M., Keller S.D. SF-36. Physial and mental health summary scales: A user’s manual. Boston: The Health Institute, New England Medical Center; 1994: 23–38.
18. Evans R.A., McAuley H., Harrison E.M., Shikotra A., Singapuri A., Sereno M., Elneima O., Docherty A.B., Lone N.I., Leavy O.C., Daines L., Baillie J.K., Brown J.S., Chalder T., De Soyza A., Diar Bakerly N., Easom N., Geddes J.R., Greening N.J., Hart N., Heaney L.G., Heller S., Howard L., Hurst J.R., Jacob J., Jenkins R.G., Jolley C., Kerr S., Kon O.M., Lewis K., Lord J.M., McCann G.P., Neubauer S., Openshaw P.J.M., Parekh D., Pfeffer P., Rahman N.M., Raman B., Richardson M., Rowland M., Semple M.G., Shah A.M., Singh S.J., Sheikh A., Thomas D., Toshner M., Chalmers J.D., Ho L.P., Horsley A., Marks M., Poinasamy K., Wain L.V., Brightling C.E.; PHOSP-COVID Collaborative Group. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir. Med. 2021; 9(11):1275–1287. doi: 10.1016/S2213-2600(21)00383-0
19. Vizel A.A., Belevskiy A.S., Vizel I.Yu., Kolesnikov P.E., Salakhova I.N. [Fatigue assessment scale: validation of the Russian-language version]. Prakticheskaya pul′monologiya = Practical pulmonology 2025; 1:62–65 (in Russian). doi: 10.24412/2409-6636-2025-13222
20. Chichanovskaya L.V., Slyusar T.A., Abramenko Yu.V., Nekrasova T.M., Slyusar I.N. [Clinical and psychological profile and quality of life in patients with post-COVID syndrome]. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 2023; 123(4):53–58 (in Russian). doi: 10.17116/jnevro202312304153
21. Sazonova E.N., Zhmerenetskiy K.V., Zhivotova E.Yu., Yakovenko I.G. [Endotheliopathy and systemic inflammation: reversibility of causal relationships in a pathological functional system (literature review)]. Regionarnoe krovoobrashchenie i mikrocirkulyaciya = Regional Blood Circulation and Microcirculation 2022; 21(4):5–15 (in Russian). doi: 10.24884/1682-6655-2022-21-4-5-15
Review
For citations:
Dudchenko L.Sh., Beloglazov V.A., Yatskov I.A., Andreeva G.N., Solovyova E.A., Shulyak I.V. Clinical significance of endothelin-1 and angiotensin-2 levels in patients with post-COVID syndrome according to the timing of rehabilitation therapy. Bulletin Physiology and Pathology of Respiration. 2026;(99):42-54. (In Russ.) https://doi.org/10.36604/1998-5029-2026-99-42-54
JATS XML























